BOSTON, Nov. 7 (Reuters) - Johnson & Johnson (JNJ.N: Quote, Profile, Research) and Schering-Plough Corp (SGP.N: Quote, Profile, Research) said on Wednesday that their experimental drug golimumab was effective in clinical trials in reducing symptoms of psoriatic arthritis and ankylosing spondylitis -- conditions related to rheumatoid arthritis.
